GlobeNewswire by notified

WillScot to Announce First Quarter 2019 Results on May 2, 2019

Share

BALTIMORE, April 22, 2019 (GLOBE NEWSWIRE) -- WillScot Corporation (“WillScot”) (NASDAQ: WSC) today announced that it will release its first quarter 2019 financial results on Thursday, May 2, 2019 after the markets close.

President and Chief Executive Officer, Bradley Soultz, and Chief Financial Officer, Timothy Boswell will host a conference call and webcast on Friday, May 3, 2019 at 10:00 a.m. EDT to discuss the results.

The live call can be accessed by dialing (855) 312-9420 (US/Canada toll-free) or (210) 874-7774 (International). A live webcast will also be accessible via the “Events & Presentations” section of the Company’s Investor Relations website https://investors.willscot.com. An archived version of the webcast will be available for 60 days following the call.

About WillScot Corporation

Headquartered in Baltimore, Maryland, WillScot Corporation is the public holding company for the Williams Scotsman family of companies in the United States, Canada and Mexico. WillScot Corporation trades on the NASDAQ stock exchange under the ticker symbol “WSC.” WillScot is the specialty rental services market leader providing innovative modular space and portable storage solutions across North America. It is the modular space supplier of choice for the construction, education, health care, government, retail, commercial, transportation, security and energy sectors. With over half a century of innovative history, organic growth and strategic acquisitions, its fleet comprises nearly 160,000 modular space and portable storage units managed through its network of over 120 locations.

Additional Information and Where to Find It

Additional information about WillScot can be found on the WillScot investor relations website at https://investors.willscot.com 

Contact Information

Investor Inquiries:

Mark Barbalato
investors@willscot.com

Media Inquiries:

Scott Junk
scott.junk@willscot.com

 

To view this piece of content from www.globenewswire.com, please give your consent at the top of this page.

About GlobeNewswire by notified

GlobeNewswire by notified
GlobeNewswire by notified
One Liberty Plaza - 165 Broadway
NY 10006 New York

https://notified.com

GlobeNewswire by notified is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.

Subscribe to releases from GlobeNewswire by notified

Subscribe to all the latest releases from GlobeNewswire by notified by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from GlobeNewswire by notified

Tenaris Announces 2024 First Quarter Results25.4.2024 22:30:25 CEST | Press release

The financial and operational information contained in this press release is based on unaudited consolidated condensed interim financial statements presented in U.S. dollars and prepared in accordance with International Financial Reporting Standards as issued by the International Accounting Standard Board and adopted by the European Union, or IFRS. Additionally, this press release includes non-IFRS alternative performance measures i.e., EBITDA, Net cash / debt, Free Cash Flow and Operating working capital days. See exhibit I for more details on these alternative performance measures. LUXEMBOURG, April 25, 2024 (GLOBE NEWSWIRE) -- Tenaris S.A. (NYSE and Mexico: TS and EXM Italy: TEN) (“Tenaris”) today announced its results for the quarter ended March 31, 2024 in comparison with its results for the quarter ended March 31, 2023. Summary of 2024 First Quarter Results (Comparison with fourth and first quarter of 2023) 1Q 20244Q 20231Q 2023Net sales ($ million)3,4423,4151%4,141(17%)Operating

Combined General Meeting of May 16, 202425.4.2024 22:30:00 CEST | Press release

Châtillon, France, April 25, 2024 Combined General Meeting of May 16, 2024 Procedures for Obtaining Information and Preparatory Documents for the Combined General Meeting DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT), a clinical-stage biopharmaceutical company focused on treatment options for food allergies and other immunologic conditions with significant unmet medical need (the “Company”), will hold its Combined General Meeting (the “General Meeting”) on May 16, 2024, at 10:00 a.m. CET at the Company’s new headquarters located at IRO Building, 107 Avenue de la République, 92320 Châtillon, France. The preliminary notice (avis de réunion) containing the detailed agenda, draft resolutions as well as instructions to participate and vote for this General Meeting was published in the French “Bulletin des Annonces Légales Obligatoires (BALO)” dated April 8, 2024 (No. 2400716). The meeting notice (avis de convocation) will be published in the BALO and in t

Millicom (Tigo) Board of Directors Appoints Marcelo Benitez as CEO25.4.2024 22:30:00 CEST | Press release

Millicom (Tigo) Board of Directors Appoints Marcelo Benitez as CEO Luxembourg, April 25, 2024 – Millicom announced today that its Board of Directors has appointed Marcelo Benitez as CEO of Millicom, effective June 1, 2024. Benitez has had a distinguished career with Millicom, having joined the company in Paraguay nearly 30 years ago and risen through the Company’s ranks to his most recent role as CEO of TIGO Panama. Benitez's selection completes the final phase of a succession planning and selection process, which included a thorough evaluation of internal and external candidates to ensure that the company's next CEO possesses the vision, experience, talent and leadership qualities necessary to deliver on Millicom's strategic plans. "After an extensive evaluation, it is clear to our Board that Marcelo is the right person to lead Millicom into the future”, indicated Mauricio Ramos, Chair of the Board of Directors of the Company. Under Marcelo’s leadership, TIGO Panama completed the succ

Mohawk Industries Reports Q1 Results25.4.2024 22:10:00 CEST | Press release

CALHOUN, Ga., April 25, 2024 (GLOBE NEWSWIRE) -- Mohawk Industries, Inc. (NYSE: MHK) today announced first quarter 2024 net earnings of $105 million and earnings per share (“EPS”) of $1.64; adjusted net earnings were $119 million, and adjusted EPS was $1.86. Net sales for the first quarter of 2024 were $2.7 billion, a decrease of 4.5% as reported and 5.5% on a legacy and constant basis versus the prior year. During the first quarter of 2023, the Company reported net sales of $2.8 billion, net earnings of $80 million and EPS of $1.26; adjusted net earnings were $112 million, and adjusted EPS was $1.75. Commenting on the Company’s first quarter results, Chairman and CEO Jeff Lorberbaum stated, “Though economic headwinds are impacting industry sales, margins and mix, our first quarter results reflected the positive effect of actions we are taking to enhance our performance. Our earnings per share rose year over year as a result of restructuring, productivity initiatives and benefits from

Biogen Receives Positive CHMP Opinion for TOFIDENCE™ (tocilizumab), a Biosimilar Referencing ROACTEMRA®25.4.2024 22:05:00 CEST | Press release

CHMP positive opinion is based on a robust analytical, non-clinical and clinical data package comparing TOFIDENCE™ to the reference product ROACTEMRA® CAMBRIDGE, Mass., April 25, 2024 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) adopted a positive opinion for TOFIDENCE™ (tocilizumab), a biosimilar monoclonal antibody referencing ROACTEMRA®1. The intravenous formulation of TOFIDENCE has been recommended for approval for the treatment of moderate to severely active rheumatoid arthritis, polyarticular juvenile idiopathic arthritis, systemic juvenile idiopathic arthritis and COVID-19. The CHMP’s positive opinion will now be referred to the European Commission (EC), which will decide whether to grant marketing authorization for TOFIDENCE. If a marketing authorization is granted by the EC, TOFIDENCE will be an addition to the existing biosimilars portfolio of three widely p

HiddenA line styled icon from Orion Icon Library.Eye